Skip to main content
Have a personal or library account? Click to login
Urokinase plasminogen activator expression in canine malignant mammary tumours by immunohistochemical study Cover

Urokinase plasminogen activator expression in canine malignant mammary tumours by immunohistochemical study

Journal of Veterinary Research
Volume 57 (2013): Issue 4 (December 2013)
By: ,  ,   and    
Open Access
|Dec 2013
References

References

  1. 1. Andreasen P.A., Kjoller L., Christensen L., Duffy M.J.: The urokinase type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997, 72, 1-22.
    Open DOISearch in Google Scholar
  2. 2. Angenete E., Langenskiöld M., Palmgren I., Falk P., Öresland T., Ivarsson M.L.: uPA and PAI-1 in rectal cancer - relationship to radiotherapy and clinical outcome. J Surg Res 2009, 153, 46-53.
    Open DOISearch in Google Scholar
  3. 3. Bailey T.R., Paulsen D.B., Sehgal I., Hosgood G.: Immunohistochemical staining of urokinase plasminogen activator-like and urokinase plasminogen activator receptor-like proteins in the urinary tract of healthy dogs. Am J Vet Res 2006, 67, 1628-1634.
    Open DOISearch in Google Scholar
  4. 4. Borgfeldt C., Casslen B., Liu C.L., Hansson S., Lecander I., Astedt B.: High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of uPA mRNA in poorly differentiated serous ovarian carcinoma. Int J Cancer 1998, 79, 588-595.
    Open DOISearch in Google Scholar
  5. 5. Blasi F., Carmeliet P.: uPAR: a versatile signaling orchestrator. Nat Rev Mol Cell Biol 2002, 3, 932-943.
    Open DOISearch in Google Scholar
  6. 6. Buo L., Meling G.I., Karlsrud T.S., Johansen H.T., Aasen A.O.: Antigen levels of urokinase plasminogen activator and its receptor at the tumour-host interface of colorectal adenocarcinomas are related to tumour aggressiveness. Hum Path 1995, 26, 1133-1138.
    Open DOISearch in Google Scholar
  7. 7. Carmeliet P., Jain R.K.: Angiogenesis in cancer and other diseases. Nature 2000, 407, 249-257.
    Open DOISearch in Google Scholar
  8. 8. Carmeliet P., Schoonjans L., Kieckens L., Ream B., Degen J., Bronson R., De Vos R., van den Oord J.J., Collen D., Mulligan R.C.: Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994, 368, 419-424.
    Open DOISearch in Google Scholar
  9. 9. Damjanovich L., Turzo C., Adany R.: Factors involved in the plasminogen activation system in human breast tumours.Thromb Haemost 1994, 71, 684-691.
    Open DOISearch in Google Scholar
  10. 10. Dublin E., Hanby A., Patel N.K., Liebman R., Barnes D.: Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumour pathology. Am J Pathol 2000, 157, 1219-1227.
    Open DOISearch in Google Scholar
  11. 11. Duffy M.J., Duggan C.: The urokinase plasminogen activator system: a rich source of tumour markers for the individualized management of patients with cancer. Clin Biochem 2004, 37, 541-548.
    Open DOISearch in Google Scholar
  12. 12. Elston C.W., Ellis I.O.: Assessment of histological grade. In:-, edited by C.W. Elston and I.O. Ellis, Churchill and Livingstone, London, 1998, pp. 365-384.
    Search in Google Scholar
  13. 13. Guo Y., Higazi A.A.R., Arakelian A., Sachais B.S., Cines D., Goldfarb R.H., Jones T.R., Kwaan H., Mazar A.P., Rabbani S.A.: A peptide derived from the non receptor binding region of urokinase plasminogen activator (uPA) inhibits tumour progression and angiogenesis and induces tumour cell death. FASEB J 2000, 14, 1400-1410.
    Open DOISearch in Google Scholar
  14. 14. Han B., Nakamura M., Zhou G., Ishii A., Nakamura A., Bai Y., Mori I., Kakudo K.: Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor. Int J Oncol 2006, 28, 807-814.
    Open DOISearch in Google Scholar
  15. 15. Han B., Nakamura M., Mori I., Nakamura Y., Kakudo K.: Urokinase-type plasminogen activator system and breast cancer. Oncol Rep 2005, 14, 105-112.
    Search in Google Scholar
  16. 16. Harbeck N., Kates R.E., Schmitt M., Gauger K., Kiechle M., Janicke F.: Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Canc 2004, 5, 348-352.
    Open DOISearch in Google Scholar
  17. 17. Hildenbrand R., Schaaf A., Dorn-Beineke A., Allgayer H., Sütterlin M., Marx A., Stroebel P.: Tumour stroma is the predominant uPA, uPAR, PAI-1expressing tissue in human breast cancer: prognostic impact. Histol Histopathol 2009, 24, 869-877.
    Search in Google Scholar
  18. 18. Hundsdorfer B., Zeilhofer H.F., Bock K.P., Dettmar P., Schmitt M., Kolki A., Pautke C., Horch H.H.: Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value. J Cranio Maxill Surg 2005, 33, 191-196.
    Open DOISearch in Google Scholar
  19. 19. Liotta L.A., Steeg P.S., Stetler-Stevenson W.G.: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991, 64, 327-336.
    Open DOISearch in Google Scholar
  20. 20. Look M.P., van Putten W.L., Duffy M.J., Harbeck N., Christensen I.J., Thomssen C., Kates R., Spyratos F., Fernö M., Eppenberger-Castori S., Sweep C.G., Ulm K., Peyrat J.P., Martin P.M., Magdelenat H., Brünner N., Duggan C., Lisboa B.W., Bendahl P.O., Quillien V., Daver A., Ricolleau G., Meijervan Gelder M.E., Manders P., Fiets W.E., Blankenstein M.A., Broët P., Romain S., Daxenbichler G., Windbichler G., Cufer T., Borstnar S., Kueng W., Beex L.V., Klijn J.G., O'Higgins N., Eppenberger U., Jänicke F., Schmitt M., Foekens J.A.: Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002, 94, 116-128.
    Search in Google Scholar
  21. 21. Misdorp W., Else R.W., Hellmen E., Lipscomb T.P.: Histological classification of the mammary tumours of the dog and the cat. In:edited by F.I. Shulman, Armed Forces Institute of Pathology, Washington DC, 1999, pp. 16-29
    Search in Google Scholar
  22. 22. Nielsen B.S., Rank F., Illemann M., Lund L.R., Danø K.: Stromal cells associated with early invasive foci in human mammary ductal carcinomacoexpress urokinase and urokinase receptor. Int J Cancer 2007, 120, 2086-2095.
    Open DOISearch in Google Scholar
  23. 23. Nielsen B.S., Sehested M., Duun S., Rank F., Timshel S., Rygaard J., Johnsen M., Danø, K.: Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer. Lab Invest 2001, 81, 1485-1501.
    Open DOISearch in Google Scholar
  24. 24. Reuning U., Magdolen V., Hapke S., Schmitt M.: Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins. Biol Chem 2003, 384, 1119-1131.
    Open DOISearch in Google Scholar
  25. 25. Santos A.A., Lopes C.C., Ribeiro J.R., Martins L.R., Santos J.C., Amorim I.F., Gärtner F., Matos A.J.: Identification of prognostic factors in canine mammary malignant tumours: a multivariable survival study. BMC Vet Res 2013, 9, doi: 10.1186/1746-6148-9-1.
    Open DOISearch in Google Scholar
  26. 26. Santos A., Lopes C., Marques R.M., Amorim I., Ribeiro J., Frias C., Vicente C., Gärtner F., Matos A.: Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours. Vet J 2011, 189, 43-48.
    Open DOISearch in Google Scholar
  27. 27. Schmitt M., Wilhelm O.G., Reuning U., Krüger A., Harbeck N., Lengyel E., Graeff H., Gänsbacher B., Kessler H., Bürgle M., Stürzebecher J., Sperl S., Magdolen V.: The urokinase plasminogen activation system as a novel target for tumour therapy. Fibrinolysis Proteol 2000, 14, 114-132.
    Open DOISearch in Google Scholar
  28. 28. Schneider J., Pollan M., Tejerina A., Sanchez J., Lucas A.R.: Accumulation of uPA-PAI-1 complexes inside the tumour cells is associated with axillary nodal invasion in progesterone- receptor-positive early breast cancer. Br J Cancer 2003, 88, 96-101.
    Open DOISearch in Google Scholar
  29. 29. Ulisse S., Baldini E., Sorrenti S., D’Armiento M.: The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targ 2009, 9, 32-71.
    Open DOISearch in Google Scholar
  30. 30. Wang Y.: The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med Res Rev 2001, 21, 146-170.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/bvip-2013-0100 | Journal eISSN: 2450-8608 (formerly 2300-3235)
Journal RSS Feed
Language: English
Page range: 587 - 591
Published on: Dec 31, 2013
Published by: National Veterinary Research Institute in Pulawy
In partnership with: Paradigm Publishing Services
Keywords:
bitches,
mammary gland tumours,
urokinase plasminogen activator,
immunohistochemistry
Related subjects:
Life sciences,
Molecular biology,
Microbiology and virology,
Life sciences, other,
Medicine,
Veterinary medicine

© 2013 Hannaneh Golshahi, Abbas Tavasoly, Annahita Rezaie, Mohammad Farhadi, published by National Veterinary Research Institute in Pulawy
This work is licensed under the Creative Commons License.

Volume 57 (2013): Issue 4 (December 2013)
Previous article
Next article